secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0001558370-24-013207
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor initiates rolling BLA submission to FDA for deramiocel in DMD cardiomyopathy
--------------------------------------------------------------------------------

- Rolling submission started Oct 9, 2024; plans to complete by end of 2024.
- BLA seeks full approval for deramiocel to treat all DMD cardiomyopathy patients.
- No approved treatments currently exist for DMD cardiomyopathy.
- Application may be eligible for priority review by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/0001558370-24-013207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024013207/capr-20241009x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer